Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes
  • CME
  • CE

LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Access expert recommendations for GLP-1 receptor agonist therapy for patients with type 2 diabetes.
Martin J. Abrahamson, MD, FACP
Zachary T. Bloomgarden, MD, MACE
Anne Peters, MD
Richard E. Pratley, MD
Robert S. Zimmerman, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: February 26, 2020 Expiration: February 25, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select appropriate GLP-1 RA therapies for patients with T2D based on their CV risk
  • Select appropriate GLP-1 RA therapies for patients with T2D based on their renal function
  • Select appropriate GLP-1 RA therapies for patients with T2D based on factors such as their glucose control or need for weight loss

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca and Novo Nordisk.
Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Zachary T. Bloomgarden, MD, MACE, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Merck, Novartis, and Sanofi and has ownership interest in Humana, Johnson & Johnson, and Novartis.
Anne Peters, MD

Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, California

Anne Peters, MD, has disclosed that she has received consulting fees from Abbott Diabetes Care, Boehringer Ingelheim, Lilly, Livongo, MannKind, Merck, Novo Nordisk, Pendulum Therapeutics, and Sanofi; has received funds for research support from Dexcom and vTv Therapeutics; and has ownership interest in Livongo, Mellitus Health, Omada Health, Pendulum Therapeutics, and Stability Health.
Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Orlando, Florida

Richard E. Pratley, MD, has disclosed that he has received funds for research support paid to his institution from Lexicon, Ligand, Lilly, Merck, Novo Nordisk, and Sanofi; consulting fees from GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; and fees for non-CME/CE services paid to his institution from Novo Nordisk.
Robert S. Zimmerman, MD

Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio

Robert Zimmerman, MD, has disclosed that he has received consulting fees from Novo Nordisk; fees for non-CME/CE services from LifeScan and Merck; and funds for research support from Bayer, Merck, and Novo Nordisk.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi, Inc.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for primary care providers, physicians, nurse practitioners, physician assistants, and the patients with diabetes under their care.

Goal

The goal of this ClinicalImpact curriculum is to improve the competence of primary care physicians, nurse practitioners, physician assistants, and other members of the healthcare team in managing type 2 diabetes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2020, through February 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices when selecting among GLP-1 RAs. The information provided is based on expert guidance of Martin J. Abrahamson, MD, FACP; Zachary T. Bloomgarden, MD, MACE; Anne Peters, MD; Richard E. Pratley, MD; and Robert Zimmerman, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Related Content

Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021

Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Neil Skolnik, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Nurse Practitioners: 1.0 AANP contact hour Released: July 13, 2020 Expired: July 12, 2021

Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.

Released: July 9, 2020

CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue